NO990002L - Blandinger for administrasjon av gener - Google Patents

Blandinger for administrasjon av gener

Info

Publication number
NO990002L
NO990002L NO990002A NO990002A NO990002L NO 990002 L NO990002 L NO 990002L NO 990002 A NO990002 A NO 990002A NO 990002 A NO990002 A NO 990002A NO 990002 L NO990002 L NO 990002L
Authority
NO
Norway
Prior art keywords
genes
administration
compounds
complex
chitosan
Prior art date
Application number
NO990002A
Other languages
English (en)
Norwegian (no)
Other versions
NO990002D0 (no
Inventor
Lisbeth Illum
Original Assignee
Danbiosyst Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614471.2A external-priority patent/GB9614471D0/en
Priority claimed from GBGB9614441.5A external-priority patent/GB9614441D0/en
Application filed by Danbiosyst Uk Ltd filed Critical Danbiosyst Uk Ltd
Publication of NO990002D0 publication Critical patent/NO990002D0/no
Publication of NO990002L publication Critical patent/NO990002L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electrotherapy Devices (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
NO990002A 1996-07-10 1999-01-04 Blandinger for administrasjon av gener NO990002L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9614471.2A GB9614471D0 (en) 1996-07-10 1996-07-10 Gene delivery to epithelial cells
GBGB9614441.5A GB9614441D0 (en) 1996-07-10 1996-07-10 Gene therapy delivery system for targeting to the lung endothelia
PCT/GB1997/001859 WO1998001160A2 (en) 1996-07-10 1997-07-10 Compositions suitable for delivery of genes to epithelial cells

Publications (2)

Publication Number Publication Date
NO990002D0 NO990002D0 (no) 1999-01-04
NO990002L true NO990002L (no) 1999-01-04

Family

ID=26309674

Family Applications (2)

Application Number Title Priority Date Filing Date
NO990002A NO990002L (no) 1996-07-10 1999-01-04 Blandinger for administrasjon av gener
NO990003A NO990003D0 (no) 1996-07-10 1999-01-04 Administreringssystem for genterapi

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO990003A NO990003D0 (no) 1996-07-10 1999-01-04 Administreringssystem for genterapi

Country Status (13)

Country Link
EP (2) EP0986404B1 (de)
JP (2) JP2001500109A (de)
KR (2) KR20000067855A (de)
AT (2) ATE216264T1 (de)
AU (2) AU726518C (de)
CA (2) CA2257300A1 (de)
DE (2) DE69712110T2 (de)
DK (1) DK0986404T3 (de)
ES (2) ES2175434T3 (de)
GB (2) GB2330532A (de)
NO (2) NO990002L (de)
PT (2) PT986404E (de)
WO (2) WO1998001161A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
JPH11246392A (ja) * 1998-03-03 1999-09-14 Makoto Otsuka 経口用固形製剤
AU3898699A (en) * 1998-05-13 1999-11-29 Regents Of The University Of Michigan, The Sustained dna delivery from structural matrices
AU763039B2 (en) 1999-04-08 2003-07-10 Genentech Inc. Composition based on oppositely-charged polypeptides
DE19940795A1 (de) * 1999-08-27 2001-03-01 Lohmann Therapie Syst Lts Schnellzerfallende Pellets auf der Basis von Chitosan
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
EP1101527B1 (de) * 1999-11-18 2004-09-29 Cognis Iberia, S.L. Mikrokapseln
FR2801811B1 (fr) * 1999-12-06 2002-05-03 Gerard Habar Procede de fabrication de microcapsules portant des charges cationiques
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
AU8737501A (en) * 2000-09-14 2002-03-26 Austin Research Inst Composition comprising immunogenic microparticles
EP1416916B1 (de) 2001-08-16 2007-10-17 Cmp Therapeutics Limited Chitin-mikropartikel und ihre medizinische verwendung
WO2003028657A2 (en) * 2001-10-03 2003-04-10 The Johns Hopkins University Compositions for oral gene therapy and methods of using same
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
NO317653B1 (no) 2002-05-03 2004-11-29 Stiftelsen Biopolymer Formulering som omfatter komplekser av kitosanoligomerer og nukleinsyre, fremgangsmate for a fremstille formuleringen samt anvendelser derav.
WO2004006893A1 (en) * 2002-07-15 2004-01-22 Feyecon Development & Implementation B.V. Method for particle precipitation using near-critical and supercritical antisolvents
US20040014698A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
US20040048260A1 (en) * 2002-09-10 2004-03-11 Fu-Hsiung Chang Transfection of nucleic acid
WO2004066975A1 (en) * 2002-12-18 2004-08-12 Hough Ear Institute Otologic nanotechnology
US7344491B1 (en) 2003-11-26 2008-03-18 Nanobiomagnetics, Inc. Method and apparatus for improving hearing
US7723311B2 (en) 2003-06-18 2010-05-25 Nanobiomagnetics, Inc. Delivery of bioactive substances to target cells
US8651113B2 (en) 2003-06-18 2014-02-18 Swr&D Inc. Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
DE10329087B4 (de) 2003-06-27 2014-02-13 Biomedical International R + D Gmbh Antigenhaltige Mikrosphären zur Allergietherapie
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
JP4674288B2 (ja) * 2004-03-31 2011-04-20 恵雄 岡畑 歯科用材料。
US7282194B2 (en) * 2004-10-05 2007-10-16 Gp Medical, Inc. Nanoparticles for protein drug delivery
CN102164618A (zh) * 2006-03-30 2011-08-24 恩根尼公司 用于体内转染肠细胞的非病毒组合物和方法
WO2007123793A2 (en) * 2006-04-04 2007-11-01 Stc.Unm Swellable particles for drug delivery
US20110033547A1 (en) * 2007-07-06 2011-02-10 Aarhus Universitet Dehydrated chitosan nanoparticles
RU2010116775A (ru) 2007-09-28 2011-11-10 Энджин, Инк. (Ca) Высококонцентрированные композиции полиплекса хитозана и нуклеиновой кислоты
RU2508093C2 (ru) * 2008-07-01 2014-02-27 Нитто Денко Корпорейшн Фармацевтическая композиция, содержащая микрочастицы с поверхностным покрытием
CN101869704A (zh) * 2010-06-08 2010-10-27 中国药科大学 单剂免疫破伤风类毒素阳离子葡聚糖微球及其制备方法
US8802076B2 (en) 2010-10-04 2014-08-12 Duke University Compositions and methods for modulating an immune response
WO2021150997A2 (en) * 2020-01-22 2021-07-29 Engene, Inc. Localized expression of therapeutic nucleic acids in lung epithelial cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046750A (en) * 1974-09-30 1977-09-06 California Institute Of Technology Ionene modified small polymeric beads
JPH03198782A (ja) * 1989-12-27 1991-08-29 Bitamin Kenkyusho:Kk 遺伝子導入用キャリアー、該キャリアーと遺伝子との複合体及び細胞への遺伝子導入法
US5972600A (en) * 1992-04-03 1999-10-26 The Regents Of The University Of California Separation of active complexes
JPH11505505A (ja) * 1994-06-27 1999-05-21 ザ・ジョンズ・ホプキンス・ユニバーシティー ターゲッティングされた遺伝子輸送システム
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
FR2724935B1 (fr) * 1994-09-27 1996-12-20 Centre Nat Rech Scient Compositions nanoparticulaires contenant des derives nucleotidiques, leur preparation et leur emploi en therapeutique
KR960016882A (ko) * 1994-11-01 1996-06-17 강재헌 치주염치료를 위한 서방출형 생분해성 제제
ATE252894T1 (de) * 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung

Also Published As

Publication number Publication date
NO990002D0 (no) 1999-01-04
EP0986404B1 (de) 2002-04-17
AU720989B2 (en) 2000-06-22
EP0986404A2 (de) 2000-03-22
EP0994726A2 (de) 2000-04-26
ES2175433T3 (es) 2002-11-16
PT994726E (pt) 2002-09-30
AU726518C (en) 2002-01-03
JP2000514086A (ja) 2000-10-24
GB9900054D0 (en) 1999-02-24
WO1998001161A3 (en) 1998-03-12
PT986404E (pt) 2002-09-30
KR20000067855A (ko) 2000-11-25
AU3454597A (en) 1998-02-02
AU3454697A (en) 1998-02-02
CA2257408A1 (en) 1998-01-15
NO990003L (no) 1999-01-04
ES2175434T3 (es) 2002-11-16
DE69712110D1 (de) 2002-05-23
KR20000023716A (ko) 2000-04-25
DE69712108T2 (de) 2002-12-12
WO1998001160A2 (en) 1998-01-15
DE69712110T2 (de) 2002-12-12
GB2330534B (en) 2000-09-06
ATE216264T1 (de) 2002-05-15
DE69712108D1 (de) 2002-05-23
AU726518B2 (en) 2000-11-09
WO1998001160A3 (en) 1998-03-05
GB2330534A (en) 1999-04-28
NO990003D0 (no) 1999-01-04
GB9900048D0 (en) 1999-02-24
GB2330532A (en) 1999-04-28
EP0994726B1 (de) 2002-04-17
WO1998001161A2 (en) 1998-01-15
ATE216265T1 (de) 2002-05-15
CA2257300A1 (en) 1998-01-15
JP2001500109A (ja) 2001-01-09
DK0986404T3 (da) 2002-05-13

Similar Documents

Publication Publication Date Title
NO990002L (no) Blandinger for administrasjon av gener
AU3229095A (en) Particle delivery
BG102125A (en) New dolastine derivatives, their preparation and application
FI963103A7 (fi) Ei-virusvektori
EP0764886A3 (de) Naphthochinonderivate und diese enthaltendes elektrolichtempfindliches Material
EP0684507A3 (de) Zerkleinern mit feinteiligen Mahl-Medien.
AU5772296A (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
AU4428496A (en) Direct gene transfer into the ruminant mammary gland
AU7908098A (en) Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones
AU3602097A (en) Genes from 20q13 amplicon and their uses
AU6874296A (en) Novel 2,3-dioxo-1,2,3,4-tetrahydro-quinoyxalinyl derivatives
AU5873498A (en) Mutant (msbb) or (htrb) genes
AU1684097A (en) Beta-secretase isolated from human 293 cells
AU6257298A (en) Breast cancer specific gene 1
WO1996032403A3 (de) Neue cytosin- und cytidinderivate
AU1227699A (en) Oxyranyle-triazoline thiones and their use as microbicides
GB2324091A (en) Metalloproteinase inhibitors
AU3698297A (en) Compositions containing at least one nucleic acid and their applications in the biomedical field, particularly in gene therapy
CA2298820A1 (en) The use of 1,3,4,6-tetrahydroxy-helianthrone and its derivatives in photodynamic therapy and certain such novel derivatives
AU3308695A (en) Regulated genes by stimulation of chondrocytes with IL-1beta
ZA891463B (en) Bacillus thuringiensis genes,toxins and methods
AU2408395A (en) New peptide active substance and production thereof
AU8074698A (en) (costal2) genes and their uses
AU4613796A (en) Medicament in particle form
AU5811196A (en) New quinoxalinedione derivatives, their production and use in pharmaceutical agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application